Zhang Yinhong

Dr. Zhang Yinhong

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
CTChengfang Tang
Chengfang Tang
LLLixin Li
Lixin Li
TCTing Chen
Ting Chen
LYLi Yulin
Li Yulin
BZBo Zhu
Bo Zhu
YHYonglan Huang
Yonglan Huang
The aim of this study was to observe the outcomes of newborn screening (NBS) in a certain population by using next-generation sequencing (NGS) as a first-tier screening test combined with tandem mass spectrometry (MS/MS). We performed a multicenter study of 29,601 newborns from eight screening centers with NBS via NGS combined with MS/MS. A custom-designed panel targeting the coding region of the 142 genes of 128 inborn errors of metabolism (IEMs) was applied as a first-tier screening test, and expanded NBS using MS/MS was executed simultaneously. In total, 52 genes associated with the 38 IEMs screened by MS/MS were analyzed. The NBS performance of these two methods was analyzed and compared respectively. A total of 23 IEMs were diagnosed via NGS combined with MS/MS. The incidence of IEMs was approximately 1 in 1287. Within separate statistical analyses, the positive predictive value (PPV) for MS/MS was 5.29%, and the sensitivity was 91.3%. However, for genetic screening alone, the PPV for NGS was 70.83%, with 73.91% sensitivity. The three most common IEMs were methylmalonic academia (MMA), primary carnitine deficiency (PCD) and phenylketonuria (PKU). The five genes with the most common carrier frequencies were PAH (1:42), PRODH (1:51), MMACHC (1:52), SLC25A13 (1:55) and SLC22A5 (1:63). Our study showed that NBS combined with NGS and MS/MS improves the performance of screening methods, optimizes the process, and provides accurate diagnoses.

19 April 2026 in Phytomedicine
Verified
Journal Article
Open access
JSJuan Sheng
Juan Sheng
QAQixian An
Qixian An
FYFubing Yu
Fubing Yu
YXYuliang Xiao
Yuliang Xiao
HDHuifeng Ding
Huifeng Ding
ZYZhang Yinhong
Zhang Yinhong
Colorectal cancer (CRC) exhibits high morbidity/mortality with poor late-stage survival, creating an urgent need for effective therapies. Although lycorine, a pyrrolophenanthridine alkaloid isolated from the traditional Chinese herb Lycoris radiata, has been confirmed to exhibit significant anti-CRC activity. the exact biological mechanism of its action remains unclear PURPOSE: The present study aimed to clarify whether lycorine exerts its anti-CRC effect by inducing ferroptosis in CRC cells (HCT-116 and RKO), and to elucidate its specific molecular mechanism. Human CRC cell lines HCT-116 and RKO were used in vitro: lentiviral transfection was applied to establish cell models with DPP3/solute carrier family 7 member 11 (SLC7A11) overexpression or knockdown, and cells were treated with lycorine, nuclear factor erythroid 2-related factor 2 (Nrf2) activator dimethyl fumarate (DMF), or Nrf2 inhibitor Nrf2 inhibitor (ML385), followed by detection of cell proliferation, apoptosis, invasion, reactive oxygen species (ROS), intracellular Fe²⁺ level, GSH/GSSG ratio, Malondialdehyde (MDA)level, 4-Hydroxynonenal (4-HNE) level and expression of related molecules. The ferroptosis-dependent effect was verified using inhibitors such as Deferoxamine(DFO). Molecular docking and enzyme activity experiments were conducted to elucidate the interaction between lycorine and DPP3. For in vivo validation, CRC xenograft models were constructed in nude mice, with tumor volume/weight monitored and hematoxylin and eosin (HE) staining, Ki67 Antigen (Ki67) detection, MDA detection, 4-HNE detection and molecular analyses of tumor tissues performed; RESULTS: Our results demonstrate that lycorine significantly inhibits cell proliferation, invasion, and migration, while promoting apoptosis and ROS generation, indicating its effective suppression of the malignant phenotype in CRC. Further studies reveal that lycorine induces ferroptosis in CRC cells. However, overexpression of DPP3 or SLC7A11, or activation of Nrf2, attenuates the anticancer activity of lycorine. Knockdown of DPP3 suppresses the malignant phenotype of CRC cells, an effect that can be significantly reversed by Nrf2 activator treatment or SLC7A11 overexpression. Additionally, SLC7A11 knockdown markedly counteracts the tumor-promoting effects induced by DPP3 overexpression. Molecular docking and enzymatic activity assays confirm the direct binding of lycorine to DPP3. Ferroptosis inhibitors significantly alleviate lycorine-induced cell death. In vivo experiments further validate this regulatory mechanism. Lycorine can directly bind to and inhibit DPP3, thereby blocking the Nrf2 signaling pathway and downregulating SLC7A11. This disruption of GSH metabolism leads to the accumulation of ROS and iron overload, ultimately inducing ferroptosis in CRC cells.

Verified
Journal Article
Open access
PDF file
LYLiang Ye
Liang Ye
ZYZhang Yinhong
Zhang Yinhong
JFJizhen Feng
Jizhen Feng
CHCidan Huang
Cidan Huang
XWXiaohua Wang
Xiaohua Wang
BZBaosheng Zhu
Baosheng Zhu
Newborn congenital hypothyroidism (CH) screening has been widely used worldwide. The objective of this study was to evaluate the effectiveness of applying biochemical and gene panel sequencing as screening tests for CH and to analyze the mutation spectrum of CH in China. Newborns were prospectively recruited from eight hospitals in China between February and December 2021. Clinical characteristics were collected. Second-generation sequencing was used to detect four CH-related genes, and the genetic patterns of the pathogenic genes were analyzed. We analyzed the relationship between genotype and biochemical phenotype. A total of 29,601 newborns were screened for CH. Gene panel sequencing identified 18 patients, including 10 patients affected by biochemically and genetically screened disorders and 8 patients affected by solely genetically screened disorders. The predictive positive value of genetic screening was 34.62%, which was much greater than that of biochemical screening alone (17.99%). A total of 94 cases of congenital thyroid dysfunction were confirmed by biochemical and genetic screening, including 30 CHs and 64 isolated hyperthyrotropinemia (HTT), with an incidence of 1/987 for CH and 1/463 for HTT, and a total incidence of 1/315 for hypothyroidism. The incidence rate and number of patients in Jinan were the highest, and the incidence rates in Shijiazhuang and Shanghai were the lowest. The gene mutation rate in this study was 19.1%, mainly DUOX2 mutation. The most common variant of DUOX2 was c.1588A>T(p.Lys530*). There was only a difference in sFT4 between groups with gene mutations and those without mutations. Genetic screening is a supplement to biochemical screening. Combining biochemical screening with genetic screening is useful for improving screening efficiency. The incidence of CH in China according to a multicenter study of nearly 30,000 NBS surveys was 1/315. DUOX2 gene mutations are commonly detected in these patients.

15 June 2025
Verified
Journal Article
Closed access
ALAo-Yu Li
Ao-Yu Li
BZBao-Sheng Zhu
Bao-Sheng Zhu
JZJin-Man Zhang
Jin-Man Zhang
YCYing Chan
Ying Chan
JLJun-Yue Lin
Jun-Yue Lin
ZYZhang Yinhong
Zhang Yinhong

21 July 2022 in Journal of Zhejiang University (Medical Sciences)
Verified
Journal Article
Closed access
YGYanling Gong
Yanling Gong
ZYZhang Yinhong
Zhang Yinhong
FLFan Liu
Fan Liu
BZBaosheng Zhu
Baosheng Zhu
XZXiaoyan Zhou
Xiaoyan Zhou
LLLi Li
Li Li
分析云南地区永久性先天性甲状腺功能减退症(CH)患儿的基因突变及其临床表型特点。 回顾性分析2016年1月至2019年1月经云南省第一人民医院诊治的40例CH患儿的临床资料,所有患儿随访至3岁,分别在患儿1、2和3岁时行格塞尔发育量表评分,评估患儿发育状况和预后。采用高通量测序检测27个已知的CH相关基因,分析基因型和临床表型之间的关系。 40例患儿中23例检出相关基因突变,突变检出率为57.5%;共检出8个基因的32种突变类型,前三位突变基因为 DUOX2、 TPO和 TSHR,突变频率分别为65.9%(29/44)、11.4%(5/44)和9.1%(4/44);17例检出 DUOX2基因突变患儿存在17种突变类型,其中p.K530*突变频次最高,占比20.7%(6/29); DUOX2杂合突变与复合杂合突变患儿的体格发育和智力发育评估差异无统计学意义( P>0.05),患儿随访至3岁均不能停药,表现为永久性CH。携带其他基因突变患儿的体格和智力发育评估也在正常范围。 云南地区永久性CH患儿 DUOX2、 TPO和 TSHR基因突变检出率较高,基因突变类型与CH患儿预后无明显相关性。